Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers.
Crescens TiuAnnie N M WongAlan HerschtalLinda MileshkinPublished in: Asia-Pacific journal of clinical oncology (2018)
The response rates and overall survival of patients with NSCLC, renal carcinoma and triple negative breast cancer of good performance status receiving anti-PD-1 therapy outside of a clinical trial are consistent with clinical trial data. However, patients with poor ECOG performance status are unlikely to respond. Careful patient selection and counseling about the potential outcomes of self-funding treatment in this setting is needed.
Keyphrases
- clinical trial
- small cell lung cancer
- phase ii
- open label
- double blind
- study protocol
- case report
- type diabetes
- stem cells
- randomized controlled trial
- skeletal muscle
- advanced non small cell lung cancer
- big data
- phase iii
- risk assessment
- metabolic syndrome
- free survival
- adipose tissue
- machine learning
- cell therapy
- deep learning
- skin cancer